Skip to main content
. 2019 May 20;203(1):58–75. doi: 10.4049/jimmunol.1900043

FIGURE 7.

FIGURE 7.

Therapeutic anti-CD40 treatment restored saliva production and reduced salivary gland inflammation. (A) Saliva production was measured after pilocarpine challenge. Young (n = 8); vehicle/PBS (n = 8); prednisolone (n = 10); and anti-CD40 at 15, 3, 0.6, and 0.12 mg/kg (n = 13, 12, 6, and 7, respectively). (B) In a separate experiment, saliva production by anti-CD40–treated mice (15 mg/kg) (n = 7) was compared with untreated mice (n = 6) at baseline. (C) Image analysis was used to determine the percentage of salivary glands that stained for B220 at study termination (minimum 4-wk anti-CD40 therapeutic treatment). Numbers of mice per group: young (n = 5); baseline (n = 11); vehicle (n = 16); prednisolone (n = 9); and anti-CD40 at 15, 3, 0.6, and 0.12 mg/kg (n = 7, 10, 15, and 6, respectively). *p < 0.05 one-way ANOVA. (D) Representative salivary gland images (original magnification, ×40) are presented showing B220+ staining for the different treatment groups.